Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • flunisolide

    - PMLiVE

    Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

    New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

    BOLDSCIENCE

    - PMLiVE

    AstraZeneca shares late-stage results for Airsupra in mild asthma patients

    More than ten million asthma exacerbations occur in the US every year

    - PMLiVE

    AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

    Up to 262 million people worldwide are affected by the chronic respiratory disease

    - PMLiVE

    Chiesi report highlights incorrect inhaler use among UK asthma patients

    The long-term lung condition affects around 7.2 million people in the UK

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    - PMLiVE

    AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

    The chronic respiratory disease is estimated to affect up to 262 million people globally

    - PMLiVE

    GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition

    The deal includes a monoclonal antibody ready to enter phase 2 development for asthma

    - PMLiVE

    AstraZeneca’s mild combination asthma reliever approved in UK

    Over two and a half million adults with mild cases of asthma could be eligible for the treatment

    - PMLiVE

    AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval

    Airsupra significantly reduces the risk of severe asthma exacerbations

    - PMLiVE

    AZ and Avillion’s asthma rescue treatment recommended by FDA Advisory Committee

    PT027 significantly reduced the risk of severe asthma exacerbations

    - PMLiVE

    Sanofi and Regeneron share positive data for asthma drug

    The trial evaluated the drug for children aged six to 11 years with moderate-to-severe asthma

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links